
    
      A Single Centre, Double-blind, Randomised, Placebo-controlled, Cross-over Phase I Study to
      Assess the Pharmacodynamics of oral AR-C165395XX after Administration of Repeated Doses for 3
      days in Subjects with Type 2 Diabetes Mellitus
    
  